Drug intelligence / Profile preview

formoterol fumarate MDI

Development stage: Discontinued
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Inhalation

Overview

Formoterol fumarate MDI (PT005) is an inhaled long-acting β2-adrenergic agonist (LABA) bronchodilator formulated as a metered dose inhaler (MDI). It is developed for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including moderate to very severe cases. The drug acts by stimulating β2-adrenergic receptors in the airway smooth muscle, leading to bronchodilation and improved airflow. PT005 uses proprietary porous particle technology to enhance stability and delivery efficiency in the MDI format. It has been evaluated both as monotherapy and as part of combination therapies for COPD[1][2][3][4][5].

Other names: FF MDIformoterol fumarate metered dose inhaler

Targets

ADRB2 (β2)

Beyond the preview

Go deeper on formoterol fumarate MDI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on formoterol fumarate MDI.

Explore the full profile